Research programme: respiratory and inflammatory disease therapeutics - Inflazyme
Alternative Names: IPL 12a,085; PDE IV inhibitors - InflazymeLatest Information Update: 07 Feb 2017
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation; Respiratory tract disorders
Most Recent Events
- 07 Feb 2017 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 07 Feb 2017 Discontinued - Preclinical for Respiratory tract disorders in USA (unspecified route)
- 05 Jun 2007 This programme is available for licensing (http://www.inflazyme.com)